Archive

Strategy, appointments, major clinical, medical and regulatory advances, and partnerships: you can find all the latest Ipsen Group press releases here.

April 22, 2021

Study Evaluating the Effect of Food on the Pharmacokinetics of Palovarotene and the Effect of Palovarotene on the Pharmacokinetics of the CYP3A4 Substrate Midazolam in Two Cohorts of Healthy Adult Subjects

Clinical Trial

June 5, 2020

Dysport in Hallux Abducto Valgus (HAV) Phase IIa

Clinical Trial

June 5, 2020

Dysport in Post-Surgical Neuralgia

Clinical Trial

June 5, 2020

Efficacy and Safety of Clostridium Botulinum Toxin Type A to Improve Appearance of Moderate to Severe Glabellar Lines

Clinical Trial

June 5, 2020

Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

Clinical Trial

June 5, 2020

Study to Evaluate a Dose of Telotristat Etiprate in Male and Female With Mild, Moderate and Severe Hepatic Insufficiency and Matched Healthy Subjects

Clinical Trial

June 5, 2020

To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)

Clinical Trial

June 5, 2020

Efficacy and Safety of Lanreotide Autogel® 60, 90 or 120 mg With Lanreotide 40 mg Prolonged Release (PR) in Acromegaly

Clinical Trial

June 5, 2020

Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly

Clinical Trial

June 5, 2020

Dysport in the Treatment of Glabellar Lines in Chinese Subjects

Clinical Trial

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2023